Kerlone

Quick links to important sections

Kerlone

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kerlone

Property Description
Active Ingredient Betaxolol Hydrochloride
Form Oral Tablets, Ophthalmic Solution
Pharmacological Class Cardioselective Beta-Blocker
General Purpose Reduction of Systemic and Intraocular Pressure
Origin Synthetic Compound

What Type of Medicine is Kerlone (Betaxolol)?

Kerlone is a prescription-only pharmaceutical entity whose active substance is the synthetic compound Betaxolol Hydrochloride. It is formally classified as a Beta-Adrenergic Receptor Antagonist, or beta-blocker. More specifically, Betaxolol is a selective beta1-adrenergic receptor antagonist, defining it as a cardioselective beta-blocker. This cardioselectivity is clinically recognized for preferentially influencing cardiac function, distinguishing it from older, non-selective analogues which affect beta receptors throughout the body.

Composition and Available Drug Forms

Kerlone is a single-ingredient product, Betaxolol Hydrochloride, available for systemic use in oral tablets and for topical use as an ophthalmic solution. For systemic administration, the drug is formulated into oral tablets consisting of the active compound combined with solid excipients, intended for the oral route of administration. The same active ingredient is also prepared in a liquid form, using an aqueous solution as its base, for topical ocular administration. The drug's classification as a cardioselective agent is validated by its ability to modulate cardiac function while minimizing undesirable effects on other systems, such as the bronchi. This indicates the medicine maintains a focused action primarily on the heart.

The General Purpose of This Cardioselective Agent

The general therapeutic purpose of this cardioselective agent is to reduce systemic pressure and decrease the overall work demanded of the heart muscle. This is accomplished because the medicine acts on beta1 receptors, slowing the heart rate and consequently reducing cardiac output. In its ophthalmic form, the compound provides a related benefit by lowering intraocular pressure via the reduction of aqueous humor secretion, which is a key physiological action of the substance. A common use scenario involves managing patients who require sustained regulation of elevated blood pressure through the drug's systemic effect.

Regulatory References

  1. U.S. National Library of Medicine (NIH/NLM Drug Information)

What side effects are possible with Kerlone?

Possible Side Effects and Safety Information

The safety profile of Kerlone (Betaxolol Hydrochloride) is officially structured by classifying possible adverse events into System-Organ-Classes (SOCs) and documenting their frequency based on regulatory standards. The primary SOCs affected include Cardiac Disorders, Vascular Disorders, Nervous System Disorders, and Eye Disorders, reflecting both the systemic (oral tablet) and local (ophthalmic solution) routes of administration.

Documented Adverse Reactions

The most frequent effects documented in official labeling include dizziness, fatigue, headache, slow heart rate (bradycardia), and cold extremities. For the ophthalmic form, ocular discomfort is classified as very common, while blurred vision and increased tearing are common.

Less frequent effects classified as rare include depression, insomnia, hypotension, and alopecia (hair loss).

Serious Adverse Reactions and Constraints

Official regulatory documents highlight the potential for serious adverse reactions, including the development of Overt Cardiac Failure or Second or Third Degree AV Block. A specific risk is noted regarding the abrupt cessation of oral therapy, which has been associated with the exacerbation of Angina Pectoris and potential for Myocardial Infarction.

Safety constraints noted in regulatory labels include the potential for beta-blockade to mask signs of acute hypoglycemia in diabetic patients or mask signs of hyperthyroidism. Specific population safety considerations exist, such as a documented reduction in clearance for individuals with renal impairment and the potential for signs of beta-blockade (e.g., bradycardia) in the neonate if the medication is administered until delivery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a Kerlone (betaxolol) overdose as a medical emergency primarily affecting the cardiovascular system.

Documented Overdose Manifestations

Symptoms and signs documented in regulatory sources reflect the drug’s effects on the heart and circulation. These include bradycardia (slow heartbeat), hypotension (low blood pressure), dizziness, and fatigue. More severe outcomes involve life-threatening conditions such as cardiac arrest, shock, coma, and acute heart failure. Respiratory distress or seizures may also occur.

Immediate Emergency Action

If an overdose is suspected or confirmed, or if severe signs such as collapse, difficulty breathing, or unresponsiveness occur, immediate medical help must be sought. Official guidance explicitly instructs contacting emergency services (such as 911 or the local emergency number) or a Poison Control center right away. The person's medicine container should be taken to the hospital.

Medical Management

Specific medical management may involve administering supportive measures and reversal agents in a supervised setting. Pharmacological intervention may include the use of atropine or glucagon to counteract profound cardiovascular depression. Monitoring in a hospital setting, including continuous ECG and vital sign surveillance, is required to manage the potential for delayed or prolonged toxicity, particularly with sustained-release forms. Pediatric patients are noted to be at a higher risk for hypoglycemia (low blood sugar) following an overdose.

Therapeutic Uses of Kerlone

Kerlone (betaxolol) is commonly used to help with the long-term management of chronic high blood pressure (hypertension) and is relevant for managing symptoms that create noticeable physiological strain. It is a therapy that may be part of symptomatic management applied across domains where additional symptomatic support is needed.


What Kerlone Treats: Main Uses and Benefits

Kerlone is commonly used to help with the long-term management of conditions involving cardiovascular strain, including chronic high blood pressure and specific issues that cause chest pain (Angina Pectoris). It is also applied in contexts where supportive management is needed for certain fast or irregular heart rhythms.

This medication is often used when symptoms intensify, providing supportive relief that contributes to easing the overall symptom load associated with these conditions. It is considered relevant in clinical settings that involve acute or unstable symptom patterns.

Quick Fact: Relief for Symptoms
Kerlone supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

By addressing the symptoms that create noticeable physiological strain, this therapy supports the patient during difficult episodes and helps manage underlying conditions, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Kerlone (betaxolol) tablets are approved for use in adults, but eligibility is strictly limited by official regulatory documentation concerning pre-existing conditions and age.

Contraindicated Populations

The medicine is contraindicated and must not be used in patients with:

  • Hypersensitivity to the drug.
  • Sinus Bradycardia (unusually slow heart rate).
  • Heart Block greater than first degree.
  • Overt Cardiac Failure or Cardiogenic Shock.
  • Untreated Pheochromocytoma.

Age and Organ Restrictions

Population Group Regulatory Status
Pediatric (Under 18) Safety and efficacy have not been established for systemic use.
Older Adults (Geriatric) Use is allowed, but regulatory labeling advises considering a reduced initial dosage due to increased potential for bradycardia.
Severe Renal Impairment Requires conditional use with a lower initial dose due to prolonged elimination half-life.

Pregnancy and Lactation

Pregnancy (FDA Category C) status restricts use only if the potential benefit justifies the potential fetal risk. The drug is not generally recommended while breastfeeding, as it is excreted into human milk.

What should I know about interactions with other medicines?

Kerlone (betaxolol) can have significant additive effects when combined with certain classes of medicines, primarily due to their shared impact on heart rate and blood pressure.

Documented Interaction Categories

Product Category Clinical Concern Mechanistic Basis
Calcium Channel Blockers (e.g., Verapamil, Diltiazem) Increased risk of severe heart block and/or left ventricular failure. Additive effects on AV conduction and myocardial contractility.
Antiarrhythmics (e.g., Amiodarone, Digitalis) Increased risk of pronounced bradycardia and hypotension. Additive effects on AV conduction and heart rate.
Catecholamine-Depleting Drugs (e.g., Reserpine) Risk of profound hypotension or severe bradycardia. Pharmacodynamic synergism resulting in an additive reduction of sympathetic activity.
Clonidine Risk of rebound hypertension upon sudden withdrawal of Clonidine. Mechanism involves the body's response to the withdrawal of a central antihypertensive agent.
General Anesthetics (e.g., Isoflurane, Propofol) Augments the risks of general anesthesia. Anesthetics that depress the myocardium can combine with Kerlone's effects.

When discontinuing therapy with Clonidine, Kerlone should be gradually reduced over several days before the withdrawal of Clonidine. Concomitant use with thiazide-type diuretics is known to result in an additive blood pressure-lowering effect. Patients concurrently receiving other oral beta-blockers or catecholamine-depleting drugs require close observation for signs of excessive bradycardia or hypotension.

Mechanism of Action

How Kerlone Works

Kerlone (betaxolol) functions as a selective antagonist of the Beta-1 (beta1) adrenergic receptors, which are densely concentrated in the cardiac tissue. By competitively binding to these receptors, Kerlone prevents their activation by endogenous catecholamines (like norepinephrine) released by the sympathetic nervous system.

This molecular blockade initiates a cascade that directly modulates the heart's function. The targeted interference with beta1 signaling leads to two core physiological consequences: a reduction in the rate of electrical discharge, known as negative chronotropy, and a decrease in the force of heart muscle contraction, known as negative inotropy.

The resulting physiological modulation extends to the systemic circulation by limiting the overall volume and rate of blood expelled (cardiac output). Furthermore, the mechanism indirectly influences pressure-regulating pathways by inhibiting the release of renin from the kidneys, altering the activity within systems that affect the systemic vascular state.

Dosage and Administration Information

How Kerlone is Used: Administration Guidelines

Kerlone (betaxolol) is administered via two distinct routes, depending on the therapeutic objective: oral for systemic treatment using tablets, and topical ocular using a solution or suspension for local effects.


Labeled Dosing Regimens

For oral systemic use, the initial dose for managing blood pressure is 10 mg once daily. The dosage may be increased after a period of 7 to 14 days if the desired response is not achieved, with a maximum dose of 40 mg per day. For topical ocular use, the standard regimen is one drop applied twice daily to the affected eye(s).


Administration Conditions and Timing

Oral absorption is unaffected by concurrent ingestion of food or alcohol. The ophthalmic suspension requires shaking well before use. If other topical eye drops are required, administration must be separated by at least 10 minutes. In the event of a missed oral dose, it should be taken as soon as remembered, unless it is nearly time for the next dose; doses should not be doubled.


Population-Specific Adjustments

Specific dosage modifications apply to certain groups. For older adults and patients with severe renal impairment or requiring dialysis, the initial oral starting dose is reduced to 5 mg once daily. Furthermore, the oral dosage for patients with severe renal impairment should not exceed 20 mg/day. Should the oral therapy need to be discontinued, the dosage must be gradually reduced over a period of two weeks.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kerlone (Betaxolol)

Evidence for Systemic Use in Chronic High Blood Pressure

The research for the oral tablets of Kerlone has primarily focused on outcomes related to systemic or functional imbalance, specifically chronic high blood pressure (hypertension). Studies included randomized controlled trials (RCTs) that compared Kerlone against both a placebo and several other existing blood pressure medications. Research examined changes in key physiological measures, including both Systolic and Diastolic Blood Pressure (SBP/DBP), measured both at rest and during exercise.

Studies reported measurements of a change in blood pressure levels 24 hours after dosing in double-blind, placebo-controlled trials. The maximum measured change in blood pressure was typically observed within the first one or two weeks of study observation. Data show patterns related to measured blood pressure change, where doses above 20 mg were not consistently associated with a statistically significant additional change compared to the 20 mg dose. Evidence remains limited for certain long-term outcomes, such as the direct reduction of cardiovascular events (like heart attack or stroke) specifically in uncomplicated hypertensive patients using Kerlone, as this evidence is often extrapolated from the broader beta-blocker class.

Evidence for Topical Use in Elevated Intraocular Pressure (Glaucoma/Ocular Hypertension)

For the ophthalmic solution, studies monitored outcomes related to functional imbalance in the eye, namely elevated Intraocular Pressure (IOP) associated with open-angle glaucoma and ocular hypertension. The evidence is derived from controlled, double-masked comparative studies, including trials against placebo and other topical eye drops.

Research highlights changes measured during the study period, reporting that the maximum observed change in IOP typically occurred around two hours after the drop was applied and persisted for a minimum of 12 hours. Findings indicate that studies observed a measured lower impact on heart rate and lung function in selected patients when compared to non-selective beta-blocker eye drops. Long-term studies lasting up to three years were conducted, but long-term research does not consistently report a continued reduction in IOP beyond the initial stabilization phase.

Evidence in Special Populations and Uncertainties

Research has specifically examined how Kerlone is processed in individuals with impaired kidney function (renal impairment). Findings indicate that in patients with moderate to severe renal impairment, the clearance of the drug was observed to be lower, and the elimination half-life was observed to be longer in these specific groups. Data for other groups, such as pediatric patients for systemic use, remain insufficient. Certainty remains low regarding the direct, large-scale reduction of cardiovascular events in uncomplicated hypertensive patients using Kerlone, as this evidence is often extrapolated from the broader beta-blocker class.

Frequently Asked Questions (FAQ)

Common questions about Kerlone (FAQ)


Q: How quickly does Kerlone start working after taking it?

Studies and official information indicate that the onset of action for the oral Kerlone tablet is described as relatively slow. While the medicine may begin working in your body soon after taking it, the full potential for a change in blood pressure levels is generally observed within a few days of consistent use.


Q: How long does the effect of a Kerlone tablet last?

Official prescribing information reflects that Kerlone is typically prescribed as a once-daily medicine. This dosing schedule is based on its duration of effect in the body, which is intended to help maintain consistent levels in the body over approximately a 24-hour period.


Q: Can Kerlone be taken at night or only in the morning?

Regulatory instructions for Kerlone state that the most important factor is consistency. The medicine should be taken at the same time every day to ensure its effects remain steady in your system.


Q: Does Kerlone need to be taken with food?

According to the official product information, the medicine’s absorption is documented as being unaffected by concurrent ingestion of food. This means the tablet can be taken with or without food.


Q: What happens if I forget to take my Kerlone dose?

Official guidance addresses how to handle a missed dose, which is outlined in the administration section of the product information.


Q: How does Kerlone differ from other beta-blockers in how it works?

Kerlone is classified as a cardioselective beta1-adrenergic receptor antagonist. Official documents note that this classification means the medicine is intended to act primarily on the heart, minimizing its effects on other systems.


Q: Why is Kerlone not recommended for some people with heart failure?

Kerlone is formally contraindicated (must not be used) in patients with Overt Cardiac Failure. Regulatory documents indicate that beta-blockers may inhibit the heart’s function required to maintain adequate circulation in certain severe cardiac conditions.


Q: Does Kerlone affect kidney function?

Research evidence indicates that in patients with moderate to severe renal impairment (impaired kidney function), the body eliminates Kerlone more slowly. Regulatory documents state that specific dosage adjustments are required for individuals with severe kidney impairment.


Q: Are there any reported interactions between Kerlone and antidepressants?

Some medicines, including certain antidepressants, may affect the body’s metabolism (how it processes the drug) of Kerlone. This potential interaction may alter the levels of Kerlone in the body, which can be associated with an increased potential for adverse effects.


Q: Is Kerlone considered a long-term medication?

Kerlone is approved for managing chronic high blood pressure (hypertension). The treatment of chronic conditions often involves continuous, long-term use as determined by a healthcare provider.


Q: How long does Kerlone stay in your system after the last dose?

The drug is eliminated primarily through liver metabolism and kidney excretion. The official labeling notes that the drug's elimination half-life is observed to be longer in patients with severe kidney impairment, which impacts how long it remains in the system.


Q: Is it normal to feel tired or dizzy when starting Kerlone?

Dizziness and fatigue are among the more commonly reported adverse effects of Kerlone. Regulatory documents indicate these effects are most likely to be seen at the beginning of treatment.


Q: Does Kerlone interact with over-the-counter pain relievers like ibuprofen?

Regulatory information indicates that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common over-the-counter pain relievers like ibuprofen, may reduce the potential for blood pressure-lowering effects associated with Kerlone.


Q: Are there any food or drink restrictions while taking Kerlone?

The medicine’s absorption is unaffected by food. However, official sources state that Kerlone and alcohol may have additive effects in lowering blood pressure. This combination has been associated with an increased potential for symptoms such as dizziness and lightheadedness.


Q: Does Kerlone affect blood sugar levels?

Regulatory documents note that Kerlone may affect blood sugar levels. Additionally, in patients with diabetes, the medicine can mask certain signs of low blood sugar (hypoglycemia), such as a rapid heartbeat.


Q: Is Kerlone used to treat conditions other than high blood pressure?

In its oral tablet form, Kerlone is approved for the management of high blood pressure (hypertension). Official sources also cite its use in a topical liquid form for treating elevated intraocular pressure associated with glaucoma.


Q: Can Kerlone cause weight gain?

Weight gain has been reported as a metabolic side effect in clinical studies and post-marketing experience with this medicine. It is listed among the possible adverse reactions.


Q: Are there any herbal supplements that interact with Kerlone?

Official patient information states that all medicines being used, including any herbal supplements and vitamins, should be reviewed by a healthcare provider.


Q: Why does Kerlone sometimes cause cold hands and feet?

The experience of cold extremities (hands and feet) is listed in official documentation as a common side effect of Kerlone. This effect is known to occur with this class of medicine.


Q: What happens if Kerlone is taken with alcohol?

Regulatory sources state that Kerlone and alcohol may have additive effects in lowering blood pressure. This combination has been associated with an increased potential for experiencing related symptoms such as dizziness and lightheadedness.


Q: Can Kerlone affect my ability to drive or operate machinery?

Regulatory information states that Kerlone may cause some people to become less alert than they are normally and can affect coordination, reaction time, or judgment.


Q: Is it necessary to have regular blood tests while taking Kerlone?

Regulatory documents state that regular monitoring with a healthcare provider is recommended to check for progress and assess for unwanted effects, such as changes in pulse and blood pressure.


Q: Do Kerlone's side effects go away over time?

Some mild effects have been observed in clinical reports to be transient (temporary) and may resolve even with continued use.


Q: Does Kerlone come in a liquid form?

The medicine is officially available as oral tablets for systemic use and a liquid ophthalmic solution or suspension for use in the eye. No oral liquid form intended for systemic administration is mentioned in official documents.


Q: Does Kerlone affect sexual function?

Decreased sex drive, impotence, or difficulty having an orgasm are effects that have been reported in patients taking Kerlone. These are listed among the possible adverse reactions for this medicine.

How should Kerlone be stored and disposed of?

The official labeling for Kerlone (betaxolol tablets) specifies mandatory conditions for storage and handling to maintain product integrity.


Storage Conditions and Protection

Kerlone must be stored at Controlled Room Temperature, which is defined as 20^circ to 25 C (68^circ to 77 F). The product must be protected from both moisture and excessive heat.

Requirement Specific Condition
Temperature 20^circ to 25 C
Container Tight, light-resistant container
Protection Avoid excessive heat and moisture

Handling and Disposal

Consistent with regulatory standards, Kerlone must be stored out of the reach of children. For disposal, the official labeling provides no specific household instructions. Unused or expired Kerlone must be discarded according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kerlone found in:

A-Z Index: